Corona Remedies schedules board meeting on May 11, 2026, to approve Q4 and FY26 audited financial results.
Board will consider recommending a final dividend for FY26, subject to shareholder approval at the AGM.
Trading window for company securities remains closed from April 1, 2026, until 48 hours after results announcement.